Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Thermo Fisher Scientific announced it received FDA 510(k) clearance to market its Optilite Freelite assays for the evaluation of monoclonal gammopathy of undetermined significance. The assays measure kappa and lambda free light chains in serum, enabling the identification of even small concentrations of monoclonal FLC proteins undetectable by serum protein electrophoresis.
October 2024—Smart In Media announced an AI enhancement to its PathoZoom LiveView microscope camera and software. This system incorporates “AI on the fly,” which allows users to run AI routines from their own microscope. Users select a region of interest in the field of view and AI results are returned in a few seconds. PDL-1, Ki67, ER, and PR are available now on Smart In Media’s AI menu.
October 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next-generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants. The partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians, and patients through rapid and affordable kitted NGS testing solutions.
October 2024—Qiagen has released a new version of its clinical decision support software Qiagen Clinical Insight Interpret. The latest release builds on the advanced artificial intelligence capabilities of QCI Interpret, including AI-derived literature searches and AI-trained phenotype-driven ranking.
October 2024—Bio-Rad Laboratories has launched annexin V conjugated to eight StarBright dyes—SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. The Annexin V StarBright conjugates support detection of early apoptotic cells by flow cytometry, offering an increased range of fluorophore options, and enable full use of all common laser lines found in flow cytometers such that common viability dye and fluorescent protein emission wavelengths can be avoided. This, combined with the narrow excitation and emission of StarBright dyes, reduces spillover and spreading to provide high-resolution data.
October 2024—Maine Molecular Quality Controls now offers Spotfire RSP Controls for the Biofire Spotfire Respiratory/Sore Throat Panel Mini assay. The controls are intended for use as an external assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of pathogens on all Biofire Spotfire respiratory assays performed on the Spotfire system. The kit contains six positive and six negative controls in 300-µL tubes. Maine Molecular Quality Controls 207-885-1072
October 2024—Johnson & Johnson announced Food and Drug Administration approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
October 2024—Adaptimmune Therapeutics announced FDA accelerated approval for Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory trial.
October 2024—Roche announced the launch of the Cobas Respiratory flex test, the first to use Roche’s novel and proprietary TAGS (temperature-activated generation of signal) technology. Developed by Roche scientists, TAGS technology uses multiplex PCR testing combined with color, temperature, and data processing to identify as many as 15 pathogens in a single PCR test. The Respiratory flex test can detect up to 12 of the most common respiratory viruses, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2. The test runs on the high-throughput Cobas 5800, 6800, and 8800 analyzers.
October 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in which Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
